These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27040854)

  • 1. Epidermal growth factor receptor (EGFR) mutations in small cell lung cancers: Two cases and a review of the literature.
    Siegele BJ; Shilo K; Chao BH; Carbone DP; Zhao W; Ioffe O; Franklin WA; Edelman MJ; Aisner DL
    Lung Cancer; 2016 May; 95():65-72. PubMed ID: 27040854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor mutations in small cell lung cancer.
    Tatematsu A; Shimizu J; Murakami Y; Horio Y; Nakamura S; Hida T; Mitsudomi T; Yatabe Y
    Clin Cancer Res; 2008 Oct; 14(19):6092-6. PubMed ID: 18829487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor mutations in small cell lung cancer: a brief report.
    Shiao TH; Chang YL; Yu CJ; Chang YC; Hsu YC; Chang SH; Shih JY; Yang PC
    J Thorac Oncol; 2011 Jan; 6(1):195-8. PubMed ID: 21178714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology.
    Norkowski E; Ghigna MR; Lacroix L; Le Chevalier T; Fadel É; Dartevelle P; Dorfmuller P; Thomas de Montpréville V
    J Thorac Oncol; 2013 Oct; 8(10):1265-71. PubMed ID: 24457237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
    De Pas T; Toffalorio F; Manzotti M; Fumagalli C; Spitaleri G; Catania C; Delmonte A; Giovannini M; Spaggiari L; de Braud F; Barberis M
    J Thorac Oncol; 2011 Nov; 6(11):1895-901. PubMed ID: 21841502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First case of combined small-cell lung cancer with adenocarcinoma harboring EML4-ALK fusion and an exon 19 EGFR mutation in each histological component.
    Toyokawa G; Taguchi K; Ohba T; Morodomi Y; Takenaka T; Hirai F; Yamaguchi M; Seto T; Takenoyama M; Sugio K; Ichinose Y
    J Thorac Oncol; 2012 Dec; 7(12):e39-e41. PubMed ID: 23154565
    [No Abstract]   [Full Text] [Related]  

  • 7. Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer.
    Tokaca N; Wotherspoon A; Nicholson AG; Fotiadis N; Thompson L; Popat S
    Lung Cancer; 2017 Sep; 111():65-68. PubMed ID: 28838401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.
    Alam N; Gustafson KS; Ladanyi M; Zakowski MF; Kapoor A; Truskinovsky AM; Dudek AZ
    Clin Lung Cancer; 2010 Sep; 11(5):E1-4. PubMed ID: 20837450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice.
    Abdelraouf F; Sharp A; Maurya M; Mair D; Wotherspoon A; Leary A; Gonzalez de Castro D; Bhosle J; Nassef A; Gaafar T; Popat S; Yap TA; O'Brien M
    BMC Res Notes; 2015 Nov; 8():688. PubMed ID: 26581482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR and erbB2 mutation status in Japanese lung cancer patients.
    Sasaki H; Shimizu S; Endo K; Takada M; Kawahara M; Tanaka H; Matsumura A; Iuchi K; Haneda H; Suzuki E; Kobayashi Y; Yano M; Fujii Y
    Int J Cancer; 2006 Jan; 118(1):180-4. PubMed ID: 16003726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.
    Suda K; Murakami I; Sakai K; Mizuuchi H; Shimizu S; Sato K; Tomizawa K; Tomida S; Yatabe Y; Nishio K; Mitsudomi T
    Sci Rep; 2015 Sep; 5():14447. PubMed ID: 26400668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
    Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
    Ichihara E; Hotta K; Nogami N; Kuyama S; Kishino D; Fujii M; Kozuki T; Tabata M; Harada D; Chikamori K; Aoe K; Ueoka H; Hosokawa S; Bessho A; Hisamoto-Sato A; Kubo T; Oze I; Takigawa N; Tanimoto M; Kiura K
    J Thorac Oncol; 2015 Mar; 10(3):486-91. PubMed ID: 25695221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma.
    Kim HR; Cho BC; Shim HS; Lim SM; Kim SK; Chang J; Kim DJ; Kim JH
    Lung Cancer; 2014 Mar; 83(3):374-82. PubMed ID: 24468202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry.
    Seo AN; Park TI; Jin Y; Sun PL; Kim H; Chang H; Chung JH
    Lung Cancer; 2014 Mar; 83(3):316-23. PubMed ID: 24412618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene mutations in small-cell lung cancer (SCLC): results of a panel of 6 genes in a cohort of Italian patients.
    Bordi P; Tiseo M; Barbieri F; Bavieri M; Sartori G; Marchetti A; Buttitta F; Bortesi B; Ambrosini-Spaltro A; Gnetti L; Silini EM; Ardizzoni A; Rossi G
    Lung Cancer; 2014 Dec; 86(3):324-8. PubMed ID: 25453846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer.
    Sasaki H; Endo K; Takada M; Kawahara M; Kitahara N; Tanaka H; Okumura M; Matsumura A; Iuchi K; Kawaguchi T; Yukiue H; Kobayashi Y; Yano M; Fujii Y
    Lung Cancer; 2006 Oct; 54(1):103-8. PubMed ID: 16890322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
    Willmore-Payne C; Holden JA; Layfield LJ
    Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer.
    Arrieta O; Cardona AF; Corrales L; Campos-Parra AD; Sánchez-Reyes R; Amieva-Rivera E; Rodríguez J; Vargas C; Carranza H; Otero J; Karachaliou N; Astudillo H; Rosell R;
    Lung Cancer; 2015 Feb; 87(2):169-75. PubMed ID: 25558790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rare epidermal growth factor receptor (EGFR) gene mutation in small cell lung carcinoma patients.
    Hwang CC; Hsieh TY; Yeh KY; Chen TP; Hua CC; Chang LC; Chen JR
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Sep; 166(3):274-279. PubMed ID: 35228756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.